Stacy Roughan serves as Quince Therapeutics’ Vice President, Corporate Communications & Investor Relations, leading external communications efforts including the strategic direction of the company’s investor relations, media engagement, digital and social communications, corporate reputation, and patient advocacy activities. To this position, she brings 25 years of corporate affairs expertise garnered from corporate and strategic consulting roles with experience that spans varied industries, including biotech, pharmaceutical, medical device, technology, energy, media, and restaurant, among others. Ms. Roughan’s core skill set centers around strategic storytelling and crafting a narrative that is differentiated and competitively compelling to provide breakthrough communications results. She also possesses extensive experience operating in complex and highly regulated businesses, including compliance with Food and Drug Administration drug discovery processes, phased clinical trials, and drug commercialization efforts, patented technologies, corporate litigation, emerging environmental, social, and governance matters, and Securities and Exchange Commission regulation. She holds a B.A. in English and Comparative Literary Studies, with a minor in Geology, from Occidental College.